medigraphic.com
Revista Médica Sinergia

2020, Número 07

Siguiente >>

Revista Médica Sinergia 2020; 5 (07)


Coagulación intravascular diseminada en el paciente con sepsis

Maya CA, Cartín RAC, Osejo RMS

Idioma: Español
Referencias bibliográficas: 21
Paginas: 1-10
Archivo PDF: 145.68 Kb.


RESUMEN

La sepsis es un proceso infeccioso altamente inflamatorio que se asocia con una incidencia significativa de mortalidad y complicaciones múltiples. Una de estas complicaciones es la coagulación intravascular diseminada que se desarrolla en casi la mitad de los pacientes con sepsis. Esto tiene como una de sus consecuencias finales la falla de múltiples órganos, por lo que no es sorprendente que la tasa de mortalidad de un paciente con sepsis y coagulación intravascular diseminada sea relativamente alta. La patogenia de la coagulación intravascular diseminada puede atribuirse a un trastorno de la coagulación iniciado por el factor tisular, con la propagación de micro coágulos y el consumo acelerado de factores de coagulación. Luego resulta en insuficiencia orgánica múltiple, diferentes trastornos hemorrágicos y, en el peor de los casos, muerte. El tratamiento actual de la coagulación intravascular diseminada tiene como objetivo tratar la enfermedad subyacente, en este caso el patógeno, además del tratamiento de soporte anticoagulante para mejorar los resultados clínicos.


REFERENCIAS (EN ESTE ARTÍCULO)

  1. Iba T, Ito T, Maruyama I, Jilma B, Brenner T, Müller MC, et al. Potential diagnostic markers for disseminated intravascular coagulation of sepsis. Blood Reviews. 2016;30(2):149–55. https://doi.org/10.1016/j.blre.2015.10.002

  2. Iba T, Thachil J. Present and future of anticoagulant therapy using antithrombin and thrombomodulin for sepsis-associated disseminated intravascular coagulation: a perspective from Japan. International Journal of Hematology. 2015Nov20;103(3):253–61. https://doi.org/10.1007/s12185-015-1904-z

  3. T, Shoko T, Deguchi Y. Clinical Investigation of Coagulation Markers for Early Detection of Sepsis-Induced Disseminated Intravascular Coagulation: A Single-Center, Prospective Observational Study. Clinical and Applied Thrombosis/Hemostasis. 2018Mar18;24(7):1082–7. https://doi.org/10.1177/1076029618762473

  4. Tsao C-M, Ho S-T, Wu C-C. Coagulation abnormalities in sepsis. Acta Anaesthesiologica Taiwanica. 2015;53(1):16–22. https://doi.org/10.1016/j.aat.2014.11.002

  5. Park JY, Park S, Park SY, Sim YS, Kim JH, Hwang YI, et al. Day 3 versus Day 1 Disseminated Intravascular Coagulation Score among Sepsis Patients: A Prospective Observational Study. Anaesthesia and Intensive Care. 2016Jan;44(1):57–64. https://doi.org/10.1177/0310057X1604400110

  6. Kudo D, Hayakawa M, Ono K, Yamakawa K. Impact of non-anticoagulant therapy on patients with sepsis-induced disseminated intravascular coagulation: A multicenter, case-control study. Thrombosis Research. 2018;163:22–9. https://doi.org/10.1016/j.thromres.2017.12.022

  7. Kudo D, Hayakawa M, Ono K, Yamakawa K. Impact of non-anticoagulant therapy on patients with sepsis-induced disseminated intravascular coagulation: A multicenter, case-control study. Thrombosis Research. 2018;163:22–9. https://doi.org/10.1016/j.thromres.2017.12.022

  8. Levi M. Pathogenesis and diagnosis of disseminated intravascular coagulation. International Journal of Laboratory Hematology. 2018;40:15–20. https://doi.org/10.1111/ijlh.12830

  9. Levi M, Sivapalaratnam S. Disseminated intravascular coagulation: an update on pathogenesis and diagnosis. Expert Review of Hematology. 2018Jul20;11(8):663–72. https://doi.org/10.1080/17474086.2018.1500173

  10. Umemura Y, Yamakawa K. Efficacy and safety of anticoagulant therapy in three specific populations with sepsis: a meta-analysis of randomized controlled trials: reply. Journal of Thrombosis and Haemostasis. 2016;14(11):2310–1. https://doi.org/10.1111/jth.13473

  11. Thachil J. Disseminated intravascular coagulation – new pathophysiological concepts and impact on management. Expert Review of Hematology. 2016Jun17;9(8):803–14. https://doi.org/10.1080/17474086.2016.1203250

  12. Okuda A, Ogura T, Imanishi M, Miyano A, Nishioka N, Higuchi K. Clinical Impact of Recombinant Soluble Thrombomodulin for Disseminated Intravascular Coagulation Associated with Severe Acute Cholangitis. Gut and Liver. 2018Jul15;12(4):471–7. https://doi.org/10.5009/gnl17489

  13. Iba T, Thachil J. Present and future of anticoagulant therapy using antithrombin and thrombomodulin for sepsis-associated disseminated intravascular coagulation: a perspective from Japan. International Journal of Hematology. 2015Nov20;103(3):253–61. https://doi.org/10.1007/s12185-015-1904-z

  14. Ikeda M, Matsumoto H, Ogura H, Hirose T, Shimizu K, Yamamoto K, et al. Circulating syndecan-1 predicts the development of disseminated intravascular coagulation in patients with sepsis. Journal of Critical Care. 2018Feb;43:48–53. https://doi.org/10.1016/j.jcrc.2017.07.049

  15. Walborn A, Rondina M, Mosier M, Fareed J, Hoppensteadt D. Endothelial Dysfunction Is Associated with Mortality and Severity of Coagulopathy in Patients with Sepsis and Disseminated Intravascular Coagulation. Clinical and Applied Thrombosis/Hemostasis. 2019;25:107602961985216. https://doi.org/10.1177/1076029619852163

  16. Levi M, van der Poll T. Coagulation and sepsis. Thrombosis Research. 2016Nov19;149:38–44. https://doi.org/10.1016/j.thromres.2016.11.007

  17. Delabranche X, Quenot J-P, Lavigne T, Mercier E, François B, Severac F, et al. Early Detection of Disseminated Intravascular Coagulation During Septic Shock. Critical Care Medicine. 2016;44(10). https://doi.org/10.1097/CCM.0000000000001836

  18. Umemura Y, Yamakawa K, Hayakawa M, Kudo D, Fujimi S. Concomitant Versus Individual Administration of Antithrombin and Thrombomodulin for Sepsis-Induced Disseminated Intravascular Coagulation: A Nationwide Japanese Registry Study. Clinical and Applied Thrombosis/Hemostasis. 2018Feb22;24(5):734–40. https://doi.org/10.1177/1076029618755948

  19. Hayakawa M, Yamakawa K, Kudo D, Ono K. Optimal Antithrombin Activity Threshold for Initiating Antithrombin Supplementation in Patients With Sepsis-Induced Disseminated Intravascular Coagulation: A Multicenter Retrospective Observational Study. Clinical and Applied Thrombosis/Hemostasis. 2018Aug;24(6):874–83. https://doi.org/10.1177/1076029618757346

  20. Akahoshi T, Sugimori H, Kaku N, Tokuda K, Nagata T, Noda E, et al. Comparison of recombinant human thrombomodulin and gabexate mesylate for treatment of disseminated intravascular coagulation (DIC) with sepsis following emergent gastrointestinal surgery: a retrospective study. European Journal of Trauma and Emergency Surgery. 2014Nov20;41(5):531–8. https://doi.org/10.1007/s00068-014-0478-4

  21. Umemura Y, Yamakawa K, Hayakawa M, Hamasaki T, Fujimi S. Screening itself for disseminated intravascular coagulation may reduce mortality in sepsis: A nationwide multicenter registry in Japan. Thrombosis Research. 2018;161:60–6. https://doi.org/10.1016/j.thromres.2017.11.023




2020     |     www.medigraphic.com